Background: Depression is now considered to have the highest disability burden of all conditions. Although treatment-resistant depression (TRD) is a key contributor to that burden, there is little understanding of the best treatment approaches for those who do not respond adequately to antidepressant treatments and specifically the effectiveness of available augmentation approaches.
Introduction
The burden of treatment resistant depression (TRD) is challenging to quantify, TRD having eluded a universal definition 1 but being prevalent and encompassing considerably greater severity, chronicity, recurrence, hospitalisation and comorbidity with both psychiatric and non-psychiatric disorders than non-resistant major depressive disorder (MDD) 2 . Despite this, TRD has been a neglected area of research with numerous reviews calling for more comprehensive evidence. Indeed, many of these reviews have considered patients as treatment resistant if they have failed one previous treatment trial (in contrast with the most popular guidelines 1 ), in part because this represents the inclusion criteria frequently used in clinical trials. One such example examined pharmacological augmentation treatments which the majority of TRD patients are treated with in practice 3 . Only when using the less stringent criteria of TRD was there sufficient evidence for a network meta-analysis in 2015 3 , and the authors reported significant efficacy of quetiapine, aripiprazole, lithium and thyroid hormone compared to placebo. However, this evidence may not apply to patients with more severe TRD. Pre-post analyses have the benefit of not requiring a placebo arm and the ability to compare effectiveness estimates between heterogeneous treatment approaches 4 . Additionally, pre-post effect sizes provide good clinical face validity as an estimate of the magnitude of effects seen with treatment in practice, incorporating both those specific to the individual modality as well as non-specific effects and the passage of time 4 .
Objectives
This review aimed to qualify and quantify the evidence of augmentation treatments for TRD, using the most common clinical definition (i.e. ≥2 failed treatments in current episode), and to compare effect sizes (ES) across psychological and pharmacological interventions. To our knowledge, this is the first meta-analysis comparing prepost treatment effects for all augmentation therapies across the two most popular treatment classes for depression in clinical practice. Specifically, our objectives were to:
1. Determine the efficacy of adjunctive interventions for TRD, through comparisons between treatment category (i.e. pharmacological or psychological), class (e.g. antipsychotics, mood stabilisers) and individual treatments. 2. Provide an indication of the acceptability and tolerability of these treatments.
Methods
Criteria for considering studies for the review
The protocol for this systematic review was published via PROSPERO 5 , where full details of the search are available and reported consistently following the PRISMA reporting guidelines.
Types of included studies
Only randomised controlled trials (RCT) of at least 10 participants, to at least one suitable augmentation treatment were included.
Types of participants
Participants must have been adults with TRD, defined as unremitted depression despite at least two courses of treatment of adequate dose and duration undertaken in the current episode (current best practice guidelines 6 ). It has been considered that both within-class (in addition to between-class) switching of antidepressants, and psychological treatments are valid contributors to a TRD definition 1 ; as such, these were permitted. Due to clear treatment distinctions, studies including patients with psychotic or bipolar depression were excluded.
Types of interventions
Patients must have been taking at least one continuation treatment prior to randomisation to a new (augmentation) intervention. The same eligibility criteria were employed for both continuation and augmentation treatments: permitted pharmacological treatments were any included in the Maudsley Treatment Inventory 1 and psychological treatments from the NICE depression guidelines 7 or those with multiple meta-analyses supporting use in depression. Eligible comparator treatments included pill placebo, another pharmacological agent, another psychological intervention, waiting list, active control, or treatment-as-usual (TAU). 
Types of outcome measures

Data collection and analyses
Article review and data extraction All search results were evaluated against inclusion criteria independently by pairs of review authors (RS, LM, RT, TM, VA, DT, VN, FP) with disparities addressed by consensus with additional review authors (AHY, AJC, BC). Following inclusion, data extraction was conducted by authors as above.
Quality assessment
The methodological quality assessment was examined using the Scottish Intercollegiate Guidelines Network (SIGN) 8 and the Cochrane risk of bias (RoB) 9 tools. Studies were assessed by two reviewers (rated as RoB high, low or unclear) for nine domains: sequence generation, allocation concealment, blinding of outcome assessors, use of intention-to -treat (ITT) analysis, comparability of randomised groups at baseline, inter-site differences in findings, the potential for selective outcome reporting and presence of for-profit bias (allegiance). Using individual criterion ratings, each study was given an overall RoB rating of low, moderate or high RoB (see Supplementary Table 1) .
Measures of treatment effect
Continuous data describing treatment effectiveness were extracted (e.g. pre-and post-severity scores, or longitudinal change in severity scores) and presented as a standardised mean difference (Hedges' g ES). Using a random effects model, meta-analyses computed a pooled ES with 95% confidence intervals (CI), p-values and the I 2 statistic. Statistical heterogeneity was considered important if I 2 exceeded 60% 9 , and explored using subgroups. The following comparisons were planned to assess the primary outcome: 1. Pooled effects of augmentation intervention/comparator categories (i.e. psychological treatment, psychological comparator, pharmacological treatment and pharmacological comparator). 2. Pooled effects of augmenters by class (e.g. SSRI, SNRI, antipsychotic, mood stabiliser). 3. Pooled effects of individual treatment interventions within above categories.
Additional comparisons
We planned to explore secondary outcomes quantitatively or qualitatively, comprising: Acceptability, tolerability, and an exploration of pairwise active-control comparisons to provide an indicated effect of treatment versus comparator trial arm, validating findings against the currently considered gold standardSubgroups used to explore heterogeneity Planned subgroups used to explore statistical heterogeneity included study quality (RoB) and trial duration, as well as participant treatment-resistance definition, continuation treatments, comorbidities, depression severity, duration of episode and treatment setting.
Changes made since protocol registration
The permitted range of treatment duration was amended from 6-26 weeks to include any duration where expectations of clinical efficacy were reported. This was to account for the variable windows of clinical efficacy between different treatment mechanisms (e.g. ketamine, which has well-documented rapid antidepressant effects). Excluding ketamine, the MTI recommends durations of 6 weeks for full clinical effect 1 ; therefore we selected to subgroup included trials of less than 6 weeks as "short-term" (this excludes rapid-onset treatments such as ketamine) 1 and those more than 26 weeks as "long-term" treatment durations.
--- Figure 1 about here ---
Results
Systematic search results
After duplicates were removed, 2246 manuscripts from the MEDLINE and ISI Web of Science databases (all years to 6 th February 2018) and hand searches were screened. Of 297 full texts reviewed, 39 articles describing 28 studies were eligible for inclusion. A PRISMA flow chart presents a breakdown of the search process ( Figure 1 ).
Characteristics of Included Studies
Within the 28 included RCTs, 5461 TRD participants were randomised. All analysed interventions were of parallelgroup studies, with ten trials (36%) conducted in North America, seven (25%) in Europe, six (21%) in Asia, four (14%) across multiple continents and one (4%) in South America. The mean study size was 199 (SD=270, range 20-1293). The duration of interventions ranged from five days (ketamine 11 ) to 18 months (long-term psychoanalytic psychotherapy 12 ), with a median duration of six weeks (IQR=2).
Characteristics of participants
Participants studied had a median age of 45 years (IQR=4), and 66% were female. All patients analysed had unremitted depression despite at least two adequate treatment trials in the current episode. Fifteen studies defined TRD fully retrospectively (using a minimum duration of previous treatments of 4 or 6 weeks) while twelve required at least one unsuccessful treatment retrospectively and one prospectively. One study undertook two treatment trials to determine treatment-resistance fully prospectively 13 . Most studies did not consider psychological treatments to contribute to TRD definition; only Fonagy et al. required one pharmacological and one psychological treatment failure as a minimum TRD criteria for study entry 12 . Table 1 contains further details. Supplementary Table 1 contains the RoB ratings across criteria and studies. Twelve studies were rated as having a low RoB 11, 12, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] , twelve had a moderate RoB [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , and four had a high RoB 13, [36] [37] [38] . The most common individual criteria rated as a high RoB were being funded and/or conducted by an industrial sponsor (twelve trials) and not applying or reporting an intention-to-treat analysis (seven trials). Blinding was not always maintained but was often maximised where possible i.e. in the ketamine trial (reportedly double-blind 11 ), psychological trials (two out of three trials report blinding of outcome assessors 12, 18 ) and open label studies (all but one 38 reporting blinded outcome raters).
Quality assessment
---Table 1 about here ---
Effectiveness of augmentation treatment
There was clinical diversity in the design (see Table 1 ), intervention and outcomes reported (see Supplementary  Table 2 ) across studies.
Primary outcomes
Pre-post meta-analyses indicated improvements in depression with all interventions examined (p < 0.001 =4.6) and did not affect heterogeneity of main analyses so were not excluded from analyses. Effects of all placebo trials (pill ES=0.78, psychological ES=0.94) exhibited findings similar to the sub-therapeutic duration pharmacological studies (ES=0.61) and consistently lower than active treatments; see Figure 2 and Table 2 . All active treatment effects are displayed in Supplementary Figure 1 and control arms in Supplementary Figure 2 .
--- Table 2 
Psychological treatment classes
The overall effect size of psychological therapies (3 studies; ES=1.43, 95%CI 0.50-2.36) contained substantial heterogeneity (I 2 =95.3), likely due to different therapeutic modalities that we were not able to subgroup further due to lack of studies. Within this analysis, cognitive-behavioural therapy (CBT) had the highest effect size of all individual treatments (one study 25 ; ES=1.74) while psychoanalytic psychotherapy had the smallest (one study 12 ; ES=0.59).
Publication bias was not apparent (detail available on request).
---Figure 2 about here ---
Secondary outcomes
Active versus control (pairwise) meta-analyses
In order to validate the pre-post method against the currently considered gold standard, we conducted pairwise active/control comparisons. Due to data availability, only three treatment classes were examinable. Despite heterogeneity of therapies and studies, these proposed that psychological treatments were more beneficial than usual care or an active control (3 studies, ES=0.45, 95%CI 0.09-0.81, I 2 =63.8). Antipsychotics showed effectiveness when compared to placebo (7 studies, ES=0.38, 95%CI 0.18-0.58, I 2 =59.4). The number of mood stabiliser studies was lower in the pairwise comparison than in pre-post analyses due to a paucity of placebo-controlled trials, and were not significantly more effective than placebo (4 studies, ES=0.13, 95%CI -0.14 to 0.39, p=0.34, I 2 =0).
Tolerability and acceptability
Tolerability and acceptability were defined differently between studies, and were not sufficiently homogeneous to consider quantitatively in meta-analyses. Eight studies reported the total number of adverse events (AEs) occurring in each arm, higher in active versus placebo arms for most interventions but equally between active and placebo arms in the d-cycloserine 16 and minocycline 17 trials. This rate might be heavily influenced by a large number of AEs occurring in a minority of patients, and of 7 studies reporting the percentage of participants experiencing at least one adverse event, most were similar between treatment arms. The highest dropout rate was in the ziprasidone intervention (41% in the lower dose arm) 26 . There was a >10% discrepancy in participant dropout between arms in this study, as well as Heresco-Levy et al. (d-cycloserine 23% versus placebo 11%) 16 and Husain et al. (minocycline 24% versus 10% placebo) 17 . No dropouts were reported in the CBT trial arms TAU and individual CBT (two patients withdrew from group CBT) 25 or from the 1-week lithium placebo-controlled study (either trial arm) 24 .
Discussion
We included 28 studies, most containing low to moderate RoB, reporting effect estimates for the most prevalent TRD augmentation treatment strategies, using the definition of TRD most often used in clinical practice.
Meta-analytic estimates of treatment effects for resistant and non-resistant depression
In contrast to TRD, progress is evolving regarding the comparative effectiveness of common treatments for MDD, exemplified by a recent, extensive network meta-analysis 39 : Cipriani et al. (2018) identified over 500 double-blind randomised trials of antidepressant monotherapy for MDD, in contrast with 28 we found for TRD augmentation, finding all to be significantly more effective than placebo. Another meta-analysis of pharmacological augmentation treatments for depression non-responsive to >1 antidepressant reported comparable effect sizes 3 . We anticipate smaller effect sizes within TRD populations. The greatest pre-post effect of augmentation that we report is for medications targeting the NMDA receptor, comprising of ketamine (antagonist), d-cycloserine (partial agonist) and minocycline (antagonist). This finding supports increasing attention towards drugs acting on this pathway, as illustrated by a network meta-analysis of pharmacological and somatic treatments for non-responsive depression reporting ketamine to have the strongest short-term efficacy of treatments studied 40 . It is notable however, that this finding was based on three studies only; population or design differences between studies may have yielded stronger effects in these trials than if directly compared with other interventions. Ketamine produced the highest effect size of the NMDA medications and is particularly challenging to maintain interviewer blinding, although Su et al. reported the trial as double blind 11 . Based on a larger number of studies, our findings also indicate that for patients with a history of two unsuccessful treatments in the current episode, aripiprazole is effective, but it is important to note that all trials investigating aripiprazole had a potential allegiance effect. The evidence is less certain (often assessed in open label designs 15, 28, 38 ) but promising for lithium. The World Federation of Societies of Biological Psychiatry Task Force recommends lithium as the first-line augmentation option for TRD, and quetiapine or aripiprazole as alternatives 41 ; however, we identified only one randomised quetiapine trial in the current review (found to be non-inferior to lithium). As such, it is clear that much more work in this field is required.
Effects of interventions versus placebo in randomised studies for TRD
Even a pill placebo response is variable under some methodological conditions, suggesting that there is some small scope for improvement for patients with TRD without augmenting with a new active treatment. The effect size and confidence intervals for placebo were heterogeneous across studies (as displayed in Supplementary Figure 2) , demonstrating that indeed there are limitations to inferring the relative effects of interventions across diverse investigations. Placebo and active treatment outcomes will have been influenced by a multitude of factors which differed across trials (including but not limited to the maintenance of blinding, analyses undertaken, inclusion criteria relating to comorbidities, severity, etc.). Notwithstanding, it does appear that as a whole both psychological and pharmacological treatments are more effective than either pill or psychological controls, even for already resistant patients. Specifically, the treatment classes whose pre-post confidence interval did not overlap with the pill placebo estimates were mood stabilisers, antipsychotics, NMDA drugs and medications with 'other' mechanisms. This was not the case for psychological treatments which contained a wide confidence interval, or for short-term treatment durations.
Effectiveness of psychological versus pharmacological intervention
For MDD, psychological therapies demonstrate overall comparable effect sizes to pharmacological interventions, according to a meta-analysis of direct comparisons 42 . The most recent review investigating psychological treatments for TRD identified only two randomised studies, both underpowered and defining TRD loosely; one had found comparable benefits of CBT and antidepressants, while the other reported clinical benefits of CBT but not antidepressants 43 . The importance of building the psychological evidence base is clear and we predict that over the next decade growing efforts in this field will reduce current uncertainty of their effectiveness for this patient population 44 
.
Many psychological trials were excluded from the current review, as they focused on chronicity or recurrence of depression rather than the number of failed treatments. This limitation reflects the lack of integration between psychological and pharmacological fields and the difficulty in operationalising a measure of treatment response particularly for past psychological therapies (including treatment adequacy, adherence, dose, duration, intensity and other factors likely to influence outcome). The COBALT RCT has been seminal in the field, finding CBT adjunct to usual care as clinically effective (odds ratio of 3.26) 45 , but was not eligible for inclusion in the current review due to only requiring non-response to 6 weeks of one ongoing antidepressant. It is important to note that for most patients with TRD, a combination of pharmacological and psychological approaches may be the most effective treatment both in terms of acute response and relapse prevention 46 although only pharmacological continuation treatments were focused on in the original studies included in this review.
Limitations and Strengths
This work highlights the weakness of the evidence base for augmentation treatments for TRD. Inconsistency of TRD definition excluded a large number of studies, and mediating and moderating factors (such as TRD or baseline severity, continuation treatments and case-mix of included patients) limited the ability to control confounders. However, 5034 participants from 23 studies exhibited consistency of findings. Limited comparable data were available on the tolerability and acceptability alongside effectiveness and we were not able to consider the influence of patient/investigator blinding, ITT analyses or allegiance effects in meta-analyses. These factors may have influenced effect sizes, although have not notably affected similar results in other reviews 4, 39 . Due to the limited number of psychological studies included, uncertainty remains over the benefit of CBT, psychoanalytic therapy and mindfulness-based cognitive therapy in this population.
Meta-analytic comparisons between treatment types have been deemed unsuitable (unless compared directly in original studies), but pre-post meta-analysis provides indications of effectiveness that can be compared between modalities. The pre-post analysis approach may show larger effect sizes due to spontaneous or natural remission, or patient expectations of effectiveness 10 but the likelihood of this is attenuated in TRD populations who have experienced non-effective treatments and have a lower natural recovery rate than MDD as a whole. These also therefore reflect effects as seen in real-world clinical practice. Pre-post analysis has the advantage of permitting comparisons between different treatment types and controls, which traditional meta-analysis is not suitable for (e.g. drug placebo pills have a larger effect than a waiting list control 4 , although no waiting list controls were examined in the present studies). In spite of these advantages it must be highlighted that indirectly comparing effect sizes between treatments in this way does not account for between-study variability (including but not limited to sociodemographic and clinical differences between patients recruited, the adequacy and delivery of treatment, and other procedural and analytic distinctions).
Clinical Implications
There has been continued controversy surrounding the comparison of psychological and medication-based treatment for depression. We have not found strong evidence that either one or the other is more effective in TRD specifically, although we highlight an urgent need for more intensive investigation of psychological therapy programs. This study also illustrates that a short duration of treatment affects outcomes more than differences between treatment modalities. However, our results indicate that both psychological and pharmacological treatments are more effective than either pill or psychological control, even for already resistant patients. Far from being 'lost causes', our findings demonstrate that more therapeutic work is needed to achieve an optimal response for this subpopulation of patients. Specifically, clinicians should not rule out CBT if it is being delivered with sufficient intensity and skilled therapists 25 . Our findings also support previous work indicating that aripiprazole and, to a lesser extent, lithium are effective treatments, supporting their current recommendation as first-line therapies 31 . Although the measured effect sizes with these two pharmacotherapies are similar to other options, the fact that they have been more thoroughly investigated in a larger number of studies underlines their status as first-choice options. Although unconfirmed, even if some medication-based treatments are shown to possess greater efficacy overall in TRD, treatment decisions should necessarily remain a clinical judgement, in which clinicians need to balance difficulties with tolerability of medications in addition to the durability of effects and, vitally, patient preference when deciding on the most appropriate treatments to use. We continue to advocate pre-post meta-analyses and network meta-analyses following future primary RCTs to provide further assistance to clinicians for predicting the optimal treatment modality/ies for patients with TRD.
Summary
Despite advances in the treatment of affective disorders, both clinical response to and tolerance of current pharmacological agents is often poor 2, 47 . This is particularly so for patients with TRD, for whom there is a wide range of treatment options that may be suitable, but very little consensus on which are the most effective and tolerable 46 . Our analyses provide both absolute (pre-post) and relative (pairwise) effect estimates for augmentation treatment strategies investigated for treatment-resistant depression, using the definition of TRD most often used in clinical practice. Based on our results, ketamine and other NMDA-targeting drugs, as well as buspirone and trazodone, hold particular promise for the future of evidence-based TRD treatments.
